The bleeding with antithrombotic therapy study 2: Rationale, design, and baseline characteristics of the participants.

ABSTRACT:

Aims

The bleeding risk of current antithrombotic strategies in clinical settings, including recently developed agents, needs to be clarified.

Methods and design

In an investigator-initiated, prospective, multicentre, observational study, patients with cerebrovascular or cardiovascular diseases who were taking oral antiplatelet or anticoagulant agents were enrolled. Compulsory multimodal magnetic resonance images were acquired at baseline to assess cerebral small vessel disease. Six-month follow-up will be performed for two years. The primary outcome is major bleeding as defined by the International Society on Thrombosis and Hemostasis.

Results

Between October 2016 and March 2019, 5306 patients (71.7 ± 11.2 years old, 1762 women) were enrolled. Previous intracranial ha

SUBMITTER: Takagi M 

PROVIDER: S-EPMC7856591 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature